首页 > 最新文献

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases最新文献

英文 中文
Bacterial co-occurrence with pulmonary TB, a respiratory tract infection (RTI): A cross-sectional study in a resource-limited setting 细菌共存肺结核,一种呼吸道感染(RTI):在资源有限的环境下的横断面研究
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2025-05-10 DOI: 10.1016/j.jctube.2025.100534
Mpho Magwalivha, Mpumelelo Casper Rikhotso, Leonard Owino Kachienga, Rendani Musoliwa, Ntshunxeko Thelma Banda, Maphepele Sara Mashilo, Thembani Tshiteme, Avheani Marry Mphaphuli, Hafsa Ali Mahamud, Sana Patel, Jean-Pierre Kabue Ngandu, Sana Patel, Natasha Potgieter, Afsatou Ndama Traoré

Background

Bacterial co-infections significantly affect the treatment outcomes of tuberculosis (TB) patients, particularly in resource-limited settings. Misdiagnosis of TB co-infections accelerate disease progression and contribute to the development of drug resistance, leading to higher mortality and morbidity rates, especially in underserved areas. This study aimed to investigate bacterial co-infections in patients with pulmonary tuberculosis in a rural Vhembe region of Limpopo, South Africa.

Materials and methods

A total of 100 sputum together with 100 blood samples were collected from TB patients who were undergoing TB treatment. DNA isolates were used as templates for PCR using the Anyplex™MTB/NTMe Assay kit, and subsequently, the Allplex™ MTB/MDR/XDRe Assay kit was used for the multiple detections of Mycobacterium tuberculosis (MTB) and resistance to first line and second line anti-TB drugs. Co-infections were determined using the Allplex™ Bacteria(I) & (II) Assay kit. HIV status of patients was determined using blood testing kits.

Results

Majority of study participants were male (55 %) and aged between 36 and 55 (54 %), while female were 46 % of the population. Bacterial species detected included non-tuberculous mycobacteria (NTM) in 67 % of participants, Aeromonas spp. (19 %), Vibrio spp. (2 %), and E. coli (2 %). Multidrug-resistant Mycobacterium tuberculosis (MTB) strains were identified in 2 % of the cohort. There was a significant association between employment status and age (p = 0.00), as well as between HIV status and age (p = 0.03). While no significant associations were found between HIV status and the presence of NTM or other bacterial co-infections (p = 0.19 and 0.21, respectively), the majority of Aeromonas spp. and NTM cases were observed among HIV-positive participants. Notably, 36 of the NTM cases occurred in individuals living with HIV.

Conclusion

The study findings suggest that age, socioeconomic status, and gender play a role in the development of TB, HIV, and other bacterial infections, which could further complicate treatment outcomes in patients. These factors likely contribute to increased vulnerability to co-infections, emphasizing the complex interplay between TB and HIV in these populations. Additionally, the study emphasises the importance of considering these socio-demographic factors in public health interventions to reduce the burden of TB-HIV co-infection and associated bacterial infections.
背景细菌合并感染显著影响结核病患者的治疗结果,特别是在资源有限的环境中。结核病合并感染的误诊加速了疾病的进展,助长了耐药性的发展,导致更高的死亡率和发病率,特别是在服务不足的地区。本研究旨在调查南非林波波省Vhembe农村地区肺结核患者的细菌合并感染情况。材料与方法对正在接受结核治疗的结核患者抽取痰液100份,血样100份。使用Anyplex™MTB/NTMe检测试剂盒将DNA分离物作为PCR模板,随后使用Allplex™MTB/MDR/XDRe检测试剂盒对结核分枝杆菌(MTB)进行多重检测,并对一线和二线抗结核药物进行耐药性检测。使用Allplex™细菌(I) &;(II)检测试剂盒。采用血液检测试剂盒检测患者的HIV感染状况。结果大多数研究参与者为男性(55%),年龄在36至55岁之间(54%),而女性占人口的46%。在67%的参与者中检测到的细菌种类包括非结核分枝杆菌(NTM),气单胞菌(19%),弧菌(2%)和大肠杆菌(2%)。在2%的队列中发现了耐多药结核分枝杆菌(MTB)菌株。就业状况与年龄之间存在显著相关性(p = 0.00), HIV状况与年龄之间存在显著相关性(p = 0.03)。虽然没有发现HIV状态与NTM或其他细菌共感染之间存在显著关联(p分别= 0.19和0.21),但在HIV阳性参与者中观察到大多数气单胞菌和NTM病例。值得注意的是,36例NTM病例发生在艾滋病毒感染者中。结论研究结果表明,年龄、社会经济地位和性别在结核病、艾滋病毒和其他细菌感染的发展中起着重要作用,这可能进一步使患者的治疗结果复杂化。这些因素可能导致合并感染的易感性增加,强调了这些人群中结核病和艾滋病毒之间复杂的相互作用。此外,该研究强调了在公共卫生干预措施中考虑这些社会人口因素的重要性,以减少结核病-艾滋病毒合并感染和相关细菌感染的负担。
{"title":"Bacterial co-occurrence with pulmonary TB, a respiratory tract infection (RTI): A cross-sectional study in a resource-limited setting","authors":"Mpho Magwalivha,&nbsp;Mpumelelo Casper Rikhotso,&nbsp;Leonard Owino Kachienga,&nbsp;Rendani Musoliwa,&nbsp;Ntshunxeko Thelma Banda,&nbsp;Maphepele Sara Mashilo,&nbsp;Thembani Tshiteme,&nbsp;Avheani Marry Mphaphuli,&nbsp;Hafsa Ali Mahamud,&nbsp;Sana Patel,&nbsp;Jean-Pierre Kabue Ngandu,&nbsp;Sana Patel,&nbsp;Natasha Potgieter,&nbsp;Afsatou Ndama Traoré","doi":"10.1016/j.jctube.2025.100534","DOIUrl":"10.1016/j.jctube.2025.100534","url":null,"abstract":"<div><h3>Background</h3><div>Bacterial co-infections significantly affect the treatment outcomes of tuberculosis (TB) patients, particularly in resource-limited settings. Misdiagnosis of TB co-infections accelerate disease progression and contribute to the development of drug resistance, leading to higher mortality and morbidity rates, especially in underserved areas. This study aimed to investigate bacterial co-infections in patients with pulmonary tuberculosis in a rural Vhembe region of Limpopo, South Africa.</div></div><div><h3>Materials and methods</h3><div>A total of 100 sputum together with 100 blood samples were collected from TB patients who were undergoing TB treatment. DNA isolates were used as templates for PCR using the Anyplex™MTB/NTMe Assay kit, and subsequently, the Allplex™ MTB/MDR/XDRe Assay kit was used for the multiple detections of <em>Mycobacterium tuberculosis</em> (MTB) and resistance to first line and second line anti-TB drugs. Co-infections were determined using the Allplex™ Bacteria(I) &amp; (II) Assay kit. HIV status of patients was determined using blood testing kits.</div></div><div><h3>Results</h3><div>Majority of study participants were male (55 %) and aged between 36 and 55 (54 %), while female were 46 % of the population. Bacterial species detected included non-tuberculous mycobacteria (NTM) in 67 % of participants, Aeromonas spp. (19 %), Vibrio spp. (2 %), and E. coli (2 %). Multidrug-resistant <em>Mycobacterium tuberculosis</em> (MTB) strains were identified in 2 % of the cohort. There was a significant association between employment status and age (p = 0.00), as well as between HIV status and age (p = 0.03). While no significant associations were found between HIV status and the presence of NTM or other bacterial co-infections (p = 0.19 and 0.21, respectively), the majority of Aeromonas spp. and NTM cases were observed among HIV-positive participants. Notably, 36 of the NTM cases occurred in individuals living with HIV.</div></div><div><h3>Conclusion</h3><div>The study findings suggest that age, socioeconomic status, and gender play a role in the development of TB, HIV, and other bacterial infections, which could further complicate treatment outcomes in patients. These factors likely contribute to increased vulnerability to co-infections, emphasizing the complex interplay between TB and HIV in these populations. Additionally, the study emphasises the importance of considering these socio-demographic factors in public health interventions to reduce the burden of TB-HIV co-infection and associated bacterial infections.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"40 ","pages":"Article 100534"},"PeriodicalIF":1.9,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143941821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse events reported with BPaL and BPaLM regimens in drug-resistant tuberculosis BPaL和BPaLM方案在耐药结核病中的不良事件报告
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2025-05-06 DOI: 10.1016/j.jctube.2025.100533
Kannan Sridharan , Gowri Sivaramakrishnan
{"title":"Adverse events reported with BPaL and BPaLM regimens in drug-resistant tuberculosis","authors":"Kannan Sridharan ,&nbsp;Gowri Sivaramakrishnan","doi":"10.1016/j.jctube.2025.100533","DOIUrl":"10.1016/j.jctube.2025.100533","url":null,"abstract":"","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"40 ","pages":"Article 100533"},"PeriodicalIF":1.9,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143921895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraspinal and intracranial Neurotuberculosis: A case report 椎管内及颅内神经结核1例
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2025-05-02 DOI: 10.1016/j.jctube.2025.100532
Zahra Bakhshi , Mohammad Ibrahim Ashkaran , Sara Nazemsadati , Hossein Mojdehipanah , Zahra Shafiei Kisomi

Background

Tuberculosis meningitis (TBM) is the most devastating form of tuberculosis (TB), causing high mortality or disability. The diagnosis of tuberculous meningitis is notably difficult due to its rapid onset and nonspecific symptoms. Early recognition and targeted treatment are the principal means of ensuring tuberculosis control. Here we report a case of tuberculosis meningitis with nonspecific symptoms including mental and cognitive impairments concomitant to Iliopsoas muscle abscess and spondylodiscitis.

Case presentation

Here we describe a case of TBM in a 38- year- old Asian male. He presented with behavioral change, back pain, progressive walking impairment and headache. Thoracic and lumbosacral MRI demonstrated Gibbus deformity with thoracic spondylodiscitis and bilateral Iliopsoas muscle abscess. Brain MRI finding included basal leptomeningeal enhancement. He was started on antituberculous therapy. During hospitalization, the patient’s level of consciousness decreased, and he was admitted to the intensive care unit. Surgery for correct kyphotic deformity was done, and the patient discharged about two months after admission.

Conclusion

Tuberculosis should be considered as a possible important etiology of acute bacterial meningitis that may commonly present as an afebrile illness in patients with gradually progressive mental and cognitive impairments or psychotic bizarre behaviors which leads to failure of early diagnosis.
结核性脑膜炎(TBM)是最具破坏性的结核病(TB)形式,造成高死亡率或致残。结核性脑膜炎的诊断由于其发病迅速和非特异性症状而特别困难。早期发现和有针对性的治疗是确保结核病得到控制的主要手段。这里我们报告一例结核性脑膜炎的非特异性症状,包括精神和认知障碍伴随髂腰肌脓肿和脊柱炎。病例报告我们在此报告一位38岁亚洲男性的TBM病例。他表现为行为改变、背部疼痛、进行性行走障碍和头痛。胸椎和腰骶部MRI表现为Gibbus畸形伴胸椎椎间盘炎和双侧髂腰肌脓肿。脑MRI发现包括基底脑膜增强。他开始接受抗结核治疗。住院期间,患者意识水平下降,住进重症监护病房。手术矫正后凸畸形,患者入院后约两个月出院。结论结核可能是急性细菌性脑膜炎的重要病因,在逐渐进行性精神和认知障碍或精神病性怪异行为的患者中,通常以发热性疾病的形式出现,导致早期诊断失败。
{"title":"Intraspinal and intracranial Neurotuberculosis: A case report","authors":"Zahra Bakhshi ,&nbsp;Mohammad Ibrahim Ashkaran ,&nbsp;Sara Nazemsadati ,&nbsp;Hossein Mojdehipanah ,&nbsp;Zahra Shafiei Kisomi","doi":"10.1016/j.jctube.2025.100532","DOIUrl":"10.1016/j.jctube.2025.100532","url":null,"abstract":"<div><h3>Background</h3><div>Tuberculosis meningitis (TBM) is the most devastating form of tuberculosis (TB), causing high mortality or disability. The diagnosis of tuberculous meningitis is notably difficult due to its rapid onset and nonspecific symptoms. Early recognition and targeted treatment are the principal means of ensuring tuberculosis control. Here we report a case of tuberculosis meningitis with nonspecific symptoms including mental and cognitive impairments concomitant to Iliopsoas muscle abscess and spondylodiscitis.</div></div><div><h3>Case presentation</h3><div>Here we describe a case of TBM in a 38- year- old Asian male. He presented with behavioral change, back pain, progressive walking impairment and headache. Thoracic and lumbosacral MRI demonstrated Gibbus deformity with thoracic spondylodiscitis and bilateral Iliopsoas muscle abscess. Brain MRI finding included basal leptomeningeal enhancement. He was started on antituberculous therapy. During hospitalization, the patient’s level of consciousness decreased, and he was admitted to the intensive care unit. Surgery for correct kyphotic deformity was done, and the patient discharged about two months after admission.</div></div><div><h3>Conclusion</h3><div>Tuberculosis should be considered as a possible important etiology of acute bacterial meningitis that may commonly present as an afebrile illness in patients with gradually progressive mental and cognitive impairments or psychotic bizarre behaviors which leads to failure of early diagnosis.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"40 ","pages":"Article 100532"},"PeriodicalIF":1.9,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mycobacterium shimoidei cavitary pneumonia: A rare case report, literature review 希莫氏分枝杆菌空洞性肺炎1例,文献复习
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2025-04-27 DOI: 10.1016/j.jctube.2025.100530
Siddartha Guru, David Ingram
Mycobacterium shimoidei is a rare non-tuberculous mycobacterium (NTM) which causes pneumonia. Since its discovery in 1975, less than 50 cases have been published and this would be only the fourth case in the US. We present a case of Mycobacterium shimoidei in a 72-year-old male with symptoms of cough, dyspnea, and weight loss with cavitary lung lesion on imaging. Sputum cultures grew Mycobacterium shimoidei in two separate collections, and the patient was treated with oral azithromycin, ethambutol, and rifabutin empirically. Though due to medication side effects rifabutin was stopped and other antibiotics were attempted based on susceptibilities but he was unable to tolerate any of them. Thus, only a two-drug regimen including ethambutol and azithromycin was used, on which he improved clinically and cavitary lung lesions decreased in size. In addition, we did a literature review and compiled 41 previously published cases of Mycobacterium shimoidei.
shimoidei分枝杆菌是一种罕见的引起肺炎的非结核分枝杆菌(NTM)。自1975年发现以来,发表的病例不到50例,这将是美国的第4例。我们报告一名72岁男性的shimoidei分枝杆菌病例,其症状为咳嗽,呼吸困难,体重减轻,影像学上有肺空洞病变。痰培养在两个不同的标本中培养出shimoidei分枝杆菌,患者经口服阿奇霉素、乙胺丁醇和利福布汀治疗。虽然由于药物副作用,利福布汀被停药,其他抗生素也被尝试过,但他无法忍受任何一种抗生素。因此,仅使用乙胺丁醇和阿奇霉素两种药物治疗方案,他的临床症状得到改善,肺空洞病变大小减小。此外,我们还进行了文献回顾,并汇编了41例先前发表的shimoidei分枝杆菌病例。
{"title":"Mycobacterium shimoidei cavitary pneumonia: A rare case report, literature review","authors":"Siddartha Guru,&nbsp;David Ingram","doi":"10.1016/j.jctube.2025.100530","DOIUrl":"10.1016/j.jctube.2025.100530","url":null,"abstract":"<div><div><em>Mycobacterium shimoidei</em> is a rare non-tuberculous mycobacterium (NTM) which causes pneumonia. Since its discovery in 1975, less than 50 cases have been published and this would be only the fourth case in the US. We present a case of <em>Mycobacterium shimoidei</em> in a 72-year-old male with symptoms of cough, dyspnea, and weight loss with cavitary lung lesion on imaging. Sputum cultures grew <em>Mycobacterium shimoidei</em> in two separate collections, and the patient was treated with oral azithromycin, ethambutol, and rifabutin empirically. Though due to medication side effects rifabutin was stopped and other antibiotics were attempted based on susceptibilities but he was unable to tolerate any of them. Thus, only a two-drug regimen including ethambutol and azithromycin was used, on which he improved clinically and cavitary lung lesions decreased in size. In addition, we did a literature review and compiled 41 previously published cases of <em>Mycobacterium shimoidei.</em></div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"40 ","pages":"Article 100530"},"PeriodicalIF":1.9,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143882887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rifampicin-resistant Mycobacterium tuberculosis and unsuccessful results from Xpert® MTB/Rif-Ultra assay in Amhara Region, Ethiopia 埃塞俄比亚阿姆哈拉地区耐利福平结核分枝杆菌和Xpert®MTB/Rif-Ultra检测结果不成功
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2025-04-25 DOI: 10.1016/j.jctube.2025.100528
Gizeaddis Belay , Hailu Getachew , Tigist Birku , Aimro Tadese , Yosef Gashaw , Michael Getie , Tazeb Molla , Molalign Tarekegn , Daniel Mekonnen , Alemayehu Abate

Background

Tuberculosis, an infectious disease caused by Mycobacterium tuberculosis (Mtb), causes 10 million new infections and 1.3 million deaths annually. The treatment of TB is hampered by the increasing incidence rate of drug resistance associated with TB. To diagnose TB and identify drug-resistant TB cases, rapid molecular technologies such as Xpert MTB/RIF, Truenat MTB, MTB Plus, and MTB-RIF Dx tests are recommended by the World Health Organization (WHO) and rolled out globally. Xpert MTB/RIF-Ultra assay is the most widely used in developing countries like Ethiopia. However, this rapid technology has inherent limitations, such as error reports, invalid results, and no results collectively reported as unsuccessful tuberculosis results. The purpose of this study was to retrospectively evaluate the trend of rifampicin resistance and unsuccessful results in the Xpert MTB/RIF-Ultra assay facility of Northwest Ethiopia.

Methods

Retrospective data archived in the Amhara Public Health Institute (APHI) TB laboratory from 2019 to 2024 were reviewed. Xpert MTB/RIF-Ultra software data were retrieved and transferred to Microsoft Excel. Then, it was checked for completeness, cleaned manually, and imported to Statistical Package for the Social Sciences (SPSS) version 25 software. The rate of mycobacterium tuberculosis (Mtb.) positives, multi-drug resistance tuberculosis (MDR-TB), and Unsuccessful results were analyzed from the total and year-wise. The final results were depicted using tables and different charts.

Results

From June 30, 2019, to June 30, 2024, a total of 587,128 sputum samples were obtained from presumptive TB patients in 111 GeneXpert sites in the Amhara Region. Of these samples analyzed using Xpert MTB/RIF-Ultra, 6.17 % (36,212/587,128) were Mtb positive. Furthermore, the overall proportion of rifampicin resistance (RR) among Mtb-confirmed cases decreased to 3.03 % (1,096/36,212) and showed a downward trend from 4.62 % (184/3979) in 2020 to 2 % (176/8806) in 2024. The overall unsuccessful results (error, invalid & no result) were 6.48 %. The rate of unsuccessful results remained above the national target of < 5 % throughout the study periods.

Conclusion and recommendation

The rate of Mtb and MDR-TB showed a decreasing trend in the last six years in Northwest Ethiopia. However, unsuccessful results remained above the national target. The cause of unsuccessful results should be investigated, and the Xpert MTB/RIF-Ultra-related quality assurance system must be enhanced to reduce the rate of Xpert MTB/RIF-Ultra unsuccessful results.
结核病是一种由结核分枝杆菌(Mtb)引起的传染病,每年造成1 000万新感染和130万人死亡。与结核病相关的耐药发病率不断上升,阻碍了结核病的治疗。为了诊断结核病和确定耐药结核病病例,世界卫生组织(世卫组织)推荐了快速分子技术,如Xpert MTB/RIF、Truenat MTB、MTB Plus和MTB-RIF Dx检测,并在全球推广。专家MTB/RIF-Ultra检测在埃塞俄比亚等发展中国家使用最为广泛。然而,这种快速的技术具有固有的局限性,例如错误报告、无效结果以及没有结果集体报告为不成功的结核病结果。本研究的目的是回顾性评估埃塞俄比亚西北部Xpert MTB/RIF-Ultra检测设备中利福平耐药趋势和不成功结果。方法回顾性分析Amhara公共卫生研究所(APHI)结核病实验室2019 - 2024年的数据。检索Xpert MTB/RIF-Ultra软件数据并将其传输到Microsoft Excel中。然后,检查它的完整性,手动清理,并导入社会科学统计软件包(SPSS)版本25软件。对结核分枝杆菌(Mtb)阳性率、耐多药结核病(MDR-TB)阳性率和不成功率进行统计分析。最后的结果用表格和不同的图表来描述。结果2019年6月30日至2024年6月30日,在阿姆哈拉地区111个GeneXpert站点共采集了587,128份推定结核病患者的痰样本。在使用Xpert MTB/RIF-Ultra分析的样本中,6.17%(36,212/587,128)为结核分枝杆菌阳性。在结核分枝杆菌确诊病例中,利福平耐药总体比例降至3.03%(1,096/36,212),并从2020年的4.62%(184/3979)下降至2024年的2%(176/8806)。整体不成功的结果(错误、无效& &;无结果)为6.48%。结果不成功的比率仍然高于国家目标。5%在整个研究期间。结论与建议埃塞俄比亚西北部地区结核分枝杆菌和耐多药结核的发病率在过去6年中呈下降趋势。然而,不成功的结果仍然高于国家目标。调查不合格率的原因,加强Xpert MTB/RIF-Ultra相关的质量保证体系,降低Xpert MTB/RIF-Ultra不合格率。
{"title":"Rifampicin-resistant Mycobacterium tuberculosis and unsuccessful results from Xpert® MTB/Rif-Ultra assay in Amhara Region, Ethiopia","authors":"Gizeaddis Belay ,&nbsp;Hailu Getachew ,&nbsp;Tigist Birku ,&nbsp;Aimro Tadese ,&nbsp;Yosef Gashaw ,&nbsp;Michael Getie ,&nbsp;Tazeb Molla ,&nbsp;Molalign Tarekegn ,&nbsp;Daniel Mekonnen ,&nbsp;Alemayehu Abate","doi":"10.1016/j.jctube.2025.100528","DOIUrl":"10.1016/j.jctube.2025.100528","url":null,"abstract":"<div><h3>Background</h3><div>Tuberculosis, an infectious disease caused by <em>Mycobacterium tuberculosis (Mtb),</em> causes 10 million new infections and 1.3 million deaths annually. The treatment of TB is hampered by the increasing incidence rate of<!--> <!-->drug resistance associated with<!--> <!-->TB. To diagnose TB and identify drug-resistant TB cases, rapid molecular technologies such as Xpert MTB/RIF, Truenat MTB, MTB Plus, and MTB-RIF Dx tests are recommended by the<!--> <!-->World Health Organization (WHO) and rolled out globally. Xpert MTB/RIF-Ultra assay is the most widely used in developing countries like Ethiopia. However, this rapid technology has inherent limitations, such as error reports, invalid results, and no results<!--> <!-->collectively reported as unsuccessful tuberculosis results. The purpose of this study was to retrospectively evaluate<!--> <!-->the trend of rifampicin resistance and unsuccessful results in the Xpert MTB/RIF-Ultra assay facility of Northwest Ethiopia.</div></div><div><h3>Methods</h3><div>Retrospective data archived in the<!--> <!-->Amhara Public Health Institute (APHI) TB laboratory from 2019 to 2024 were reviewed. Xpert MTB/RIF-Ultra software data were retrieved and transferred to Microsoft Excel. Then, it was checked for completeness, cleaned manually, and imported to Statistical Package for the Social Sciences (SPSS) version 25 software. The rate of <em>mycobacterium tuberculosis (Mtb.)</em> positives, multi-drug resistance tuberculosis (MDR-TB), and Unsuccessful results were analyzed from the total and year-wise. The final results were depicted using tables and different charts.</div></div><div><h3>Results</h3><div>From June 30, 2019, to June 30, 2024, a total of 587,128 sputum samples were obtained from presumptive TB patients in 111 GeneXpert sites in the<!--> <!-->Amhara Region. Of these samples analyzed using Xpert MTB/RIF-Ultra, 6.17 % (36,212/587,128) were Mtb positive. Furthermore, the overall proportion of rifampicin resistance (RR) among Mtb-confirmed cases decreased to 3.03 % (1,096/36,212) and showed a downward trend from 4.62 % (184/3979) in 2020 to 2 % (176/8806) in 2024. The overall unsuccessful results (error, invalid &amp; no result) were 6.48 %. The rate of unsuccessful results remained above the national target of &lt; 5 % throughout the study periods.</div></div><div><h3>Conclusion and recommendation</h3><div>The rate of <em>Mtb</em> and MDR-TB showed a decreasing trend in the last six years in Northwest Ethiopia. However, unsuccessful results remained above the national target. The cause of unsuccessful results should be investigated, and the Xpert MTB/RIF-Ultra-related quality assurance system must be enhanced to reduce the rate of Xpert MTB/RIF-Ultra unsuccessful results.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"40 ","pages":"Article 100528"},"PeriodicalIF":1.9,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143882889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimation of therapeutic threshold for tuberculosis using adapted nominal group technique and clinical vignettes in clinical and community settings in Southern Africa 在南部非洲的临床和社区环境中,使用适应的名义小组技术和临床小插曲估计结核病的治疗阈值
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2025-04-24 DOI: 10.1016/j.jctube.2025.100529
Alfred Kipyegon Keter , Alastair Van Heerden , Tom Decroo , Tom Boyles , Shannon Bosman , Thandanani Madonsela , Lindani Innocent Msimango , Lenika Naiken , Carlos Kiyan , Mashaete Kamele , Irene Ayakaka , Klaus Reither , Bart Karl Mario Jacobs , Lutgarde Lynen

Background

When confronted with diagnostic uncertainty and a decision on whether to start treatment or not, clinicians consider the potential harm and benefit of offering versus withholding treatment. Treatment can be offered if the probability of tuberculosis (TB) in the patient is above the “therapeutic threshold” (ThT): the probability of disease at which the expected utility of treating and not treating is the same. We estimated ThT for TB in clinical and community settings in Southern Africa using two methods: an adapted nominal group technique (aNGT), and decisions made based on clinical vignettes (CVs).

Methods

We enrolled health professionals involved in the routine management of TB patients in South Africa and Lesotho. The participants elicited, discussed and refined the harms of false positive (FP) and false negative (FN) treatment decisions for stable ambulatory patients in the clinical and community settings. They weighed all harms according to their importance in treatment decisions by distributing 100 points. ThT, calculated as the sum of the weights of the harms of the FP decision divided by the total weight, was estimated using a hierarchical Beta regression model. For the CVs, participants were presented with ten hypothetical TB cases in each setting and asked to indicate whether they would offer TB treatment or not. ThT was estimated using the generalized linear model for binary outcomes.

Results

We enrolled 138 health professionals (aNGT: 123, CVs: 130 and 115 in both). Using aNGT, the overall ThT was 37.7% (95% credible intervals (95% CrI): 35.8–39.8) and 38.2% (95% CrI: 35.9–40.6) in the clinical and community settings, respectively. Compared to aNGT, CVs produced a significantly lower estimate in the clinical setting (27.7%; 95% CrI: 23.8–31.3) but similar in the community setting (37.7%; 95% CrI: 33.1–41.7). We did not find significant differences across the subgroups defined by the measured covariates.

Conclusion

The aNGT produced a reliable estimate of ThT. The difference in the estimates of ThT between the aNGT and CVs may have a limited impact on clinical decisions. Factors influencing ThT and the acceptability of results by healthcare workers will be explored in focus group discussions and in-depth interviews.
当面临诊断的不确定性和是否开始治疗的决定时,临床医生会考虑提供治疗与不提供治疗的潜在危害和益处。如果患者患结核病的概率高于“治疗阈值”(ThT),则可以提供治疗:治疗和不治疗的预期效用相同的疾病概率。我们在南部非洲的临床和社区环境中使用两种方法估计了ThT治疗结核病的效果:一种是经过调整的名义群体技术(aNGT),另一种是基于临床小片段(CVs)做出的决定。方法我们招募了南非和莱索托参与结核病患者常规管理的卫生专业人员。参与者引出,讨论和完善假阳性(FP)和假阴性(FN)治疗决策对临床和社区环境中稳定的门诊患者的危害。他们根据危害在治疗决策中的重要性,分配100分来衡量所有危害。ThT计算为FP决策的危害权重之和除以总权重,使用分层Beta回归模型估计。在这些履历中,参与者在每种情况下都有10个假设的结核病病例,并被要求表明他们是否会提供结核病治疗。使用二元结果的广义线性模型估计ThT。结果共纳入138名卫生专业人员(aNGT: 123, cv: 130和115)。使用aNGT,在临床和社区环境中,总体ThT分别为37.7%(95%可信区间(95% CrI): 35.8-39.8)和38.2% (95% CrI: 35.9-40.6)。与aNGT相比,CVs在临床环境中产生了明显较低的估计(27.7%;95% CrI: 23.8-31.3),但在社区环境中相似(37.7%;95% CrI: 33.1-41.7)。我们没有发现测量协变量定义的亚组之间有显著差异。结论aNGT对ThT有可靠的估计。在aNGT和cv之间的ThT估计值的差异可能对临床决策的影响有限。通过焦点小组讨论和深度访谈,探讨影响ThT的因素和医护人员对结果的可接受性。
{"title":"Estimation of therapeutic threshold for tuberculosis using adapted nominal group technique and clinical vignettes in clinical and community settings in Southern Africa","authors":"Alfred Kipyegon Keter ,&nbsp;Alastair Van Heerden ,&nbsp;Tom Decroo ,&nbsp;Tom Boyles ,&nbsp;Shannon Bosman ,&nbsp;Thandanani Madonsela ,&nbsp;Lindani Innocent Msimango ,&nbsp;Lenika Naiken ,&nbsp;Carlos Kiyan ,&nbsp;Mashaete Kamele ,&nbsp;Irene Ayakaka ,&nbsp;Klaus Reither ,&nbsp;Bart Karl Mario Jacobs ,&nbsp;Lutgarde Lynen","doi":"10.1016/j.jctube.2025.100529","DOIUrl":"10.1016/j.jctube.2025.100529","url":null,"abstract":"<div><h3>Background</h3><div>When confronted with diagnostic uncertainty and a decision on whether to start treatment or not, clinicians consider the potential harm and benefit of offering versus withholding treatment. Treatment can be offered if the probability of tuberculosis (TB) in the patient is above the “therapeutic threshold” (ThT): the probability of disease at which the expected utility of treating and not treating is the same. We estimated ThT for TB in clinical and community settings in Southern Africa using two methods: an adapted nominal group technique (aNGT), and decisions made based on clinical vignettes (CVs).</div></div><div><h3>Methods</h3><div>We enrolled health professionals involved in the routine management of TB patients in South Africa and Lesotho. The participants elicited, discussed and refined the harms of false positive (FP) and false negative (FN) treatment decisions for stable ambulatory patients in the clinical and community settings. They weighed all harms according to their importance in treatment decisions by distributing 100 points. ThT, calculated as the sum of the weights of the harms of the FP decision divided by the total weight, was estimated using a hierarchical Beta regression model. For the CVs, participants were presented with ten hypothetical TB cases in each setting and asked to indicate whether they would offer TB treatment or not. ThT was estimated using the generalized linear model for binary outcomes.</div></div><div><h3>Results</h3><div>We enrolled 138 health professionals (aNGT: 123, CVs: 130 and 115 in both). Using aNGT, the overall ThT was 37.7% (95% credible intervals (95% CrI): 35.8–39.8) and 38.2% (95% CrI: 35.9–40.6) in the clinical and community settings, respectively. Compared to aNGT, CVs produced a significantly lower estimate in the clinical setting (27.7%; 95% CrI: 23.8–31.3) but similar in the community setting (37.7%; 95% CrI: 33.1–41.7). We did not find significant differences across the subgroups defined by the measured covariates.</div></div><div><h3>Conclusion</h3><div>The aNGT produced a reliable estimate of ThT. The difference in the estimates of ThT between the aNGT and CVs may have a limited impact on clinical decisions. Factors influencing ThT and the acceptability of results by healthcare workers will be explored in focus group discussions and in-depth interviews.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"40 ","pages":"Article 100529"},"PeriodicalIF":1.9,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143882888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cascade of care for the diagnosis and treatment of latent tuberculosis infection in an inner-city hospital prenatal clinic 内城医院产前门诊对潜伏性结核感染诊断和治疗的级联护理
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2025-04-18 DOI: 10.1016/j.jctube.2025.100527
Jay Phansalkar , Rajas Karajgikar , Jai Patel , Shauna Williams , Lisa Gittens-Williams , Alfred A. Lardizabal
Treating latent tuberculosis infection (LTBI) is a core intervention in reducing the burden of tuberculosis. Treatment for LTBI is challenging due to the many steps in the process, collectively termed the cascade of care. In pregnant patients with LTBI, these challenges are heightened due to the medical and social intricacies introduced by pregnancy. In this study, we evaluate the effectiveness of a screening intervention for LTBI in the prenatal clinic of an inner-city hospital in the United States, and analyze the cascade of care to identify areas for improvement. Of the n = 99 patients who had a positive QuantiFERON Gold Test (QFN), 96.7 % had a chest x-ray (CXR) ordered by their provider, 95.6 % completed the CXR, 82.8 % were referred to the TB clinic, 44.4 % scheduled an appointment with the TB clinic, 23.2 % attended an appointment at the TB clinic, 21.2 % started medical treatment of LTBI, and 17.2 % completed LTBI treatment. Together this data shows that majority of patients in the prenatal clinic with a positive QFN do not complete LTBI treatment. Most patients are lost during the steps that transition them from obstetric care to the care of the TB clinic. Improving the cascade of care for LTBI will require increased education of patients on the importance of treating LTBI, and improving the process that transitions patients from obstetric care to the care of the TB clinic.
治疗潜伏性结核感染(LTBI)是减轻结核病负担的核心干预措施。LTBI的治疗是具有挑战性的,因为在这个过程中有许多步骤,统称为级联护理。在LTBI的怀孕患者中,由于怀孕带来的医疗和社会复杂性,这些挑战更加突出。在这项研究中,我们评估了筛查干预LTBI在美国市中心医院产前诊所的有效性,并分析了护理级联,以确定需要改进的领域。在量化铁金试验(QFN)阳性的n = 99名患者中,96.7%的患者接受了医生的胸部x光检查,95.6%完成了x光检查,82.8%被转介到结核病诊所,44.4%预约了结核病诊所,23.2%参加了结核病诊所的预约,21.2%开始接受LTBI治疗,17.2%完成了LTBI治疗。这些数据表明,大多数QFN阳性的产前门诊患者没有完成LTBI治疗。大多数患者在从产科护理转向结核病诊所护理的过程中失去了生命。改善LTBI的护理级联将需要加强对患者的教育,使其了解治疗LTBI的重要性,并改进将患者从产科护理过渡到结核病诊所护理的过程。
{"title":"Cascade of care for the diagnosis and treatment of latent tuberculosis infection in an inner-city hospital prenatal clinic","authors":"Jay Phansalkar ,&nbsp;Rajas Karajgikar ,&nbsp;Jai Patel ,&nbsp;Shauna Williams ,&nbsp;Lisa Gittens-Williams ,&nbsp;Alfred A. Lardizabal","doi":"10.1016/j.jctube.2025.100527","DOIUrl":"10.1016/j.jctube.2025.100527","url":null,"abstract":"<div><div>Treating latent tuberculosis infection (LTBI) is a core intervention in reducing the burden of tuberculosis. Treatment for LTBI is challenging due to the many steps in the process, collectively termed the cascade of care. In pregnant patients with LTBI, these challenges are heightened due to the medical and social intricacies introduced by pregnancy. In this study, we evaluate the effectiveness of a screening intervention for LTBI in the prenatal clinic of an inner-city hospital in the United States, and analyze the cascade of care to identify areas for improvement. Of the n = 99 patients who had a positive QuantiFERON Gold Test (QFN), 96.7 % had a chest x-ray (CXR) ordered by their provider, 95.6 % completed the CXR, 82.8 % were referred to the TB clinic, 44.4 % scheduled an appointment with the TB clinic, 23.2 % attended an appointment at the TB clinic, 21.2 % started medical treatment of LTBI, and 17.2 % completed LTBI treatment. Together this data shows that majority of patients in the prenatal clinic with a positive QFN do not complete LTBI treatment. Most patients are lost during the steps that transition them from obstetric care to the care of the TB clinic. Improving the cascade of care for LTBI will require increased education of patients on the importance of treating LTBI, and improving the process that transitions patients from obstetric care to the care of the TB clinic.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"39 ","pages":"Article 100527"},"PeriodicalIF":1.9,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143854975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refractory splenic tuberculosis in acute myeloid Leukemia: The role of advanced diagnostics and surgical intervention 急性髓性白血病难治性脾结核:先进诊断和手术干预的作用
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2025-04-11 DOI: 10.1016/j.jctube.2025.100525
Hongju Yan, Qin Wen, Xi Zhang
AML patients are at a high risk of opportunistic infections, with tuberculosis (TB) being a common and challenging one. The immunosuppression caused by both AML and its treatment heightens this risk. Diagnosing TB in AML patients is difficult due to the overlapping symptoms of AML and TB. This case report presents a 22-year-old man diagnosed with AML who developed disseminated TB, manifesting as a refractory tuberculous splenic abscess. Despite achieving complete remission from initial induction chemotherapy, the patient experienced persistent fever. Next-generation sequencing revealed Mycobacterium tuberculosis infection, and anti-TB treatment was initiated. Despite regular anti-tuberculosis therapy, the patient continued to have recurrent fevers, with progressive splenic enlargement and an increase in splenic lesions. Eventually, splenectomy confirmed the presence of abscess-type splenic tuberculosis and resolved the symptoms. Despite the recurrence of leukemia in the bone marrow and the development of central nervous system leukemia during the patient’s treatment, complete remission was achieved again after re - induction chemotherapy and intrathecal chemotherapy. Then the patient underwent successful HSCT. This case highlights the diagnostic and therapeutic challenges in managing disseminated TB in AML patients. It underscores the importance of early and accurate diagnosis using advanced molecular techniques, close monitoring, and aggressive treatment. Surgical interventions should also be considered when standard treatments fail. Additionally, it emphasizes the need for proactive TB screening and prevention strategies in high-risk populations, such as AML patients undergoing chemotherapy.
急性髓性白血病患者机会性感染的风险很高,其中结核病是一种常见且具有挑战性的感染。AML及其治疗引起的免疫抑制增加了这种风险。由于AML和TB的症状重叠,诊断AML患者的结核病很困难。这个病例报告提出了一个22岁的男性诊断为急性髓性白血病谁发展为播散性结核,表现为难治性结核性脾脓肿。尽管从最初的诱导化疗中获得完全缓解,但患者仍出现持续发烧。新一代测序显示结核分枝杆菌感染,并开始抗结核治疗。尽管定期抗结核治疗,患者仍有反复发热,并伴有进行性脾肿大和脾病变增加。最终经脾切除术证实为脓肿型脾结核,症状得到缓解。尽管在治疗期间骨髓白血病复发,中枢神经系统白血病发展,患者在再诱导化疗和鞘内化疗后再次完全缓解。然后,患者接受了成功的HSCT。本病例突出了在AML患者中管理播散性结核的诊断和治疗挑战。它强调了使用先进分子技术进行早期准确诊断、密切监测和积极治疗的重要性。当标准治疗失败时,也应考虑手术干预。此外,它强调需要在高危人群(如接受化疗的急性髓性白血病患者)中开展积极的结核病筛查和预防策略。
{"title":"Refractory splenic tuberculosis in acute myeloid Leukemia: The role of advanced diagnostics and surgical intervention","authors":"Hongju Yan,&nbsp;Qin Wen,&nbsp;Xi Zhang","doi":"10.1016/j.jctube.2025.100525","DOIUrl":"10.1016/j.jctube.2025.100525","url":null,"abstract":"<div><div>AML patients are at a high risk of opportunistic infections, with tuberculosis (TB) being a common and challenging one. The immunosuppression caused by both AML and its treatment heightens this risk. Diagnosing TB in AML patients is difficult due to the overlapping symptoms of AML and TB. This case report presents a 22-year-old man diagnosed with AML who developed disseminated TB, manifesting as a refractory tuberculous splenic abscess. Despite achieving complete remission from initial induction chemotherapy, the patient experienced persistent fever. Next-generation sequencing revealed Mycobacterium tuberculosis infection, and anti-TB treatment was initiated. Despite regular anti-tuberculosis therapy, the patient continued to have recurrent fevers, with progressive splenic enlargement and an increase in splenic lesions. Eventually, splenectomy confirmed the presence of abscess-type splenic tuberculosis and resolved the symptoms. Despite the recurrence of leukemia in the bone marrow and the development of central nervous system leukemia during the patient’s treatment, complete remission was achieved again after re - induction chemotherapy and intrathecal chemotherapy. Then the patient underwent successful HSCT. This case highlights the diagnostic and therapeutic challenges in managing disseminated TB in AML patients. It underscores the importance of early and accurate diagnosis using advanced molecular techniques, close monitoring, and aggressive treatment. Surgical interventions should also be considered when standard treatments fail. Additionally, it emphasizes the need for proactive TB screening and prevention strategies in high-risk populations, such as AML patients undergoing chemotherapy.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"40 ","pages":"Article 100525"},"PeriodicalIF":1.9,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143918379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bridging gaps in tuberculosis control: addressing cross-border challenges between India and Pakistan 弥合结核病控制方面的差距:应对印度和巴基斯坦之间的跨界挑战
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2025-04-11 DOI: 10.1016/j.jctube.2025.100526
Harendra Kumar , Fnu Teena , Aneeta Bai , Love Kumar , Sebastian Gallego
Tuberculosis (TB) continues to pose a substantial public health concern in South Asia, especially in India and Pakistan, which together represent a considerable portion of the worldwide TB burden. Notwithstanding national initiatives, international cooperation in tuberculosis control is insufficient, presenting a considerable obstacle to disease eradication. This viewpoint underscores the pressing need for improved collaboration between the two nations to tackle common difficulties, such as multidrug-resistant tuberculosis (MDR-TB), inadequate data exchange, and inconsistencies in treatment procedures. We suggest a framework to enhance bilateral tuberculosis control efforts via enhanced data-sharing methods, standardization of treatment regimens, collaborative research projects, and cross-border healthcare access. The formation of a regional tuberculosis task force and health corridors, equipped with diagnostic and treatment facilities, may improve disease monitoring and patient care, particularly in border areas. Moreover, combined training programs for healthcare professionals and legislative measures might enhance a more synchronized response. The World Health Organization (WHO) advocates for a worldwide plan to eradicate tuberculosis, presenting India and Pakistan with the potential to use international collaborations, like the Worldwide Fund and the Stop TB Partnership, to deploy novel diagnostic methods and therapies. A cohesive approach to tuberculosis enhances regional health security and establishes a benchmark for wider infectious disease management efforts. This viewpoint emphasizes the need for a collaborative strategy for tuberculosis control, promoting policy-oriented initiatives that surpass political divisions to attain a shared objective—diminishing tuberculosis incidence and enhancing public health outcomes in both countries.
在南亚,特别是在印度和巴基斯坦,结核病继续构成一个重大的公共卫生问题,这两个国家加起来占世界结核病负担的相当大一部分。尽管有国家倡议,但在结核病控制方面的国际合作不足,这对根除疾病构成了相当大的障碍。这一观点强调了两国之间迫切需要改善合作,以解决共同的困难,例如耐多药结核病(MDR-TB)、数据交换不足以及治疗程序不一致。我们建议建立一个框架,通过加强数据共享方法、标准化治疗方案、合作研究项目和跨境医疗保健获取来加强双边结核病控制工作。成立一个区域结核病工作队和配备诊断和治疗设施的保健走廊,可改善疾病监测和病人护理,特别是在边境地区。此外,针对医疗保健专业人员的联合培训计划和立法措施可能会加强更同步的反应。世界卫生组织(世卫组织)倡导一项全球根除结核病计划,使印度和巴基斯坦有可能利用国际合作,如世界基金和控制结核病伙伴关系,部署新的诊断方法和治疗方法。统一的结核病防治办法可加强区域卫生安全,并为更广泛的传染病管理工作确立基准。这一观点强调需要制定一项结核病控制合作战略,促进超越政治分歧的以政策为导向的举措,以实现两国减少结核病发病率和提高公共卫生成果的共同目标。
{"title":"Bridging gaps in tuberculosis control: addressing cross-border challenges between India and Pakistan","authors":"Harendra Kumar ,&nbsp;Fnu Teena ,&nbsp;Aneeta Bai ,&nbsp;Love Kumar ,&nbsp;Sebastian Gallego","doi":"10.1016/j.jctube.2025.100526","DOIUrl":"10.1016/j.jctube.2025.100526","url":null,"abstract":"<div><div>Tuberculosis (TB) continues to pose a substantial public health concern in South Asia, especially in India and Pakistan, which together represent a considerable portion of the worldwide TB burden. Notwithstanding national initiatives, international cooperation in tuberculosis control is insufficient, presenting a considerable obstacle to disease eradication. This viewpoint underscores the pressing need for improved collaboration between the two nations to tackle common difficulties, such as multidrug-resistant tuberculosis (MDR-TB), inadequate data exchange, and inconsistencies in treatment procedures. We suggest a framework to enhance bilateral tuberculosis control efforts via enhanced data-sharing methods, standardization of treatment regimens, collaborative research projects, and cross-border healthcare access. The formation of a regional tuberculosis task force and health corridors, equipped with diagnostic and treatment facilities, may improve disease monitoring and patient care, particularly in border areas. Moreover, combined training programs for healthcare professionals and legislative measures might enhance a more synchronized response. The World Health Organization (WHO) advocates for a worldwide plan to eradicate tuberculosis, presenting India and Pakistan with the potential to use international collaborations, like the Worldwide Fund and the Stop TB Partnership, to deploy novel diagnostic methods and therapies. A cohesive approach to tuberculosis enhances regional health security and establishes a benchmark for wider infectious disease management efforts. This viewpoint emphasizes the need for a collaborative strategy for tuberculosis control, promoting policy-oriented initiatives that surpass political divisions to attain a shared objective—diminishing tuberculosis incidence and enhancing public health outcomes in both countries.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"39 ","pages":"Article 100526"},"PeriodicalIF":1.9,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypical presentations of mucocutaneous TB in HIV: A case series from South Africa 非典型表现的粘膜皮肤结核艾滋病毒:来自南非的病例系列
IF 1.9 Q3 INFECTIOUS DISEASES Pub Date : 2025-04-06 DOI: 10.1016/j.jctube.2025.100524
Mahlatse Cordelia Kgokolo , Mohlominyane Jeffrey Mokheseng , Jabulile Johanna Makhubele , Shalate Charlotte Siwele , Tinashe Irvin Maphosa , Tsholofelo Kungoane

Introduction

Tuberculosis (TB) remains a major burden of disease worldwide, especially in Human immunodeficiency virus (HIV)-infected patients. Cutaneous forms of TB account for approximately 10 % of all extrapulmonary tuberculosis cases, with oral manifestations accounting for less than 1 % of these cases. A high index of suspicion is essential when diagnosing rare clinical presentations. The response to treatment is excellent in most patients, particularly those receiving concomitant, effective antiretroviral (ARV) treatment.

Patient presentation

We report two cases of lupus vulgaris in AIDS patients (CD4 count of 113 cells/mm3 and 172 cells/mm3, respectively) and one case of mucosal TB in a patient with CD4 count of 365 cells/mm3. All the patients were adults referred to the dermatology clinic. The atypical clinical presentations included papules, plaques, and ulcers affecting unusual sites, such as the upper and lower limbs in the case of lupus vulgaris and a tongue ulcer in the patient with oral TB, emphasizing the importance of strong suspicion in HIV-infected patients. All available diagnostic measures were used to confirm the diagnosis.

Management

We demonstrate the importance of multidisciplinary care for patients and an excellent response to anti-TB treatment once diagnosed. We also emphasize the importance of concomitant ARV treatment and patient follow-up.

Conclusion

The outcomes of two of the three patients were good, highlighting the importance of timely clinical diagnosis and treatment, including monitoring and follow-up, while ensuring continued ARV treatment.
结核病(TB)仍然是世界范围内疾病的主要负担,特别是在人类免疫缺陷病毒(HIV)感染患者中。皮肤结核约占所有肺外结核病例的10% %,口腔结核占这些病例的不到1% %。在诊断罕见的临床表现时,高度怀疑是必不可少的。大多数患者对治疗的反应非常好,特别是那些同时接受有效抗逆转录病毒(ARV)治疗的患者。我们报告了2例艾滋病患者的寻常性狼疮(CD4计数分别为113细胞/mm3和172细胞/mm3)和1例粘膜结核患者的CD4计数为365细胞/mm3。所有的患者都是转介到皮肤科诊所的成年人。非典型临床表现包括丘疹、斑块和影响不寻常部位的溃疡,如寻常性狼疮患者的上肢和下肢以及口腔结核患者的舌溃疡,这强调了对hiv感染患者进行强烈怀疑的重要性。所有可用的诊断方法均用于确诊。我们证明了多学科治疗对患者的重要性,以及一旦诊断出抗结核治疗的良好反应。我们还强调同时进行抗逆转录病毒治疗和患者随访的重要性。结论3例患者中2例预后良好,突出了及时临床诊断和治疗的重要性,包括监测和随访,同时确保持续抗逆转录病毒治疗。
{"title":"Atypical presentations of mucocutaneous TB in HIV: A case series from South Africa","authors":"Mahlatse Cordelia Kgokolo ,&nbsp;Mohlominyane Jeffrey Mokheseng ,&nbsp;Jabulile Johanna Makhubele ,&nbsp;Shalate Charlotte Siwele ,&nbsp;Tinashe Irvin Maphosa ,&nbsp;Tsholofelo Kungoane","doi":"10.1016/j.jctube.2025.100524","DOIUrl":"10.1016/j.jctube.2025.100524","url":null,"abstract":"<div><h3>Introduction</h3><div>Tuberculosis (TB) remains a major burden of disease worldwide, especially in Human immunodeficiency virus (HIV)-infected patients. Cutaneous forms of TB account for approximately 10 % of all extrapulmonary tuberculosis cases, with oral manifestations accounting for less than 1 % of these cases. A high index of suspicion is essential when diagnosing rare clinical presentations. The response to treatment is excellent in most patients, particularly those receiving concomitant, effective antiretroviral (ARV) treatment.</div></div><div><h3>Patient presentation</h3><div>We report two cases of lupus vulgaris in AIDS patients (CD4 count of 113 cells/mm<sup>3</sup> and 172 cells/mm<sup>3</sup>, respectively) and one case of mucosal TB in a patient with CD4 count of 365 cells/mm<sup>3</sup>. All the patients were adults referred to the dermatology clinic. The atypical clinical presentations included papules, plaques, and ulcers affecting unusual sites, such as the upper and lower limbs in the case of lupus vulgaris and a tongue ulcer in the patient with oral TB, emphasizing the importance of strong suspicion in HIV-infected patients. All available diagnostic measures were used to confirm the diagnosis.</div></div><div><h3>Management</h3><div>We demonstrate the importance of multidisciplinary care for patients and an excellent response to anti-TB treatment once diagnosed. We also emphasize the importance of concomitant ARV treatment and patient follow-up.</div></div><div><h3>Conclusion</h3><div>The outcomes of two of the three patients were good, highlighting the importance of timely clinical diagnosis and treatment, including monitoring and follow-up, while ensuring continued ARV treatment.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"40 ","pages":"Article 100524"},"PeriodicalIF":1.9,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143891649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1